Biography

Dr. Mackie is a Distinguished Professor of Psychological and Brain Sciences at Indiana University Bloomington and an Adjunct Professor of Anesthesiology at Indiana University School of Medicine.  He is also a Linda and Jack Gill Chair and the former Director of the Gill Institute for Biomolecular Science at Indiana University Bloomington.  He received his M.D. from Yale University, and completed an internship and residency at Yale University and the University of Washington, respectively.  He did post-doctoral work at Rockefeller University and the University of Washington.  For fifteen years he combined an active laboratory-based program in cannabinoid research with clinical care in anesthesiology at the University of Washington.  In 2007 he was recruited to Indiana University Bloomington as a Gill Chair in neuroscience.  Dr. Mackie’s research interests focus on understanding the relationships between phytocannabinoids (such as THC and CBD), terpenes, endocannabinoids, and the pharmacological and physiological responses to both.  His special interests include the potential detrimental effects of cannabis on the developing brain as well as potential therapeutic benefits of modulating the endocannabinoid system.  His lab takes diverse approaches (imaging, electrophysiological, behavioral, molecular, and biochemical) to address these questions. 

Publications

  • Hill MN, Mackie K. 2023. Cannabinoids: Endogenous and otherwise—14th Ed. in Goodman and Gilman's: The Pharmacological Basis of Therapeutics. 
    (Ed. L.L. Brunton, B.C. Knollmann, and R. Hilal-Dandan) McGraw Hill. p. 505-518.
  • Lee MT, Mackie K, Chiou LC. Alternative pain management via endocannabinoids in the time of the opioid epidemic: Peripheral neuromodulation and pharmacological interventions. Br J Pharmacol. 2023. 180(7): p.894-909.
  • Xu J, Cai H, Wu Z, Li X, Tian C, Ao Z, Niu VC, Xiao X, Jiang L, Khodoun M, Rothenberg M, Mackie K, Chen J, Lee LP, Guo F. Acoustic metamaterials-driven transdermal drug delivery for rapid and on-demand management of acute disease. Nat Commun. 2023. 14(1): p.869.
  • Carey LM, Xu Z, Rajic G, Makriyannis A, Romero J, Hillard C, Mackie K, Hohmann AG. Peripheral sensory neuron CB2 cannabinoid receptors are necessary for both CB2-mediated antinociceptive efficacy and sparing of morphine tolerance in a mouse model of anti-retroviral toxic neuropathy. Pharmacol Res. 2023. 187: p.106560.
  • Dvorakova M, Wilson S, Corey W, Billingsley J, Zimmowitch A, Tracey J, Straiker A, Mackie K. A Critical Evaluation of Terpenoid Signaling at Cannabinoid CB1 Receptors in a Neuronal Model. Molecules. 2022. 27(17).
  • Straiker A, Wilson S, Corey W, Dvorakova M, Bosquez T, Tracey J, Wilkowski C, Ho K, Wager-Miller J, Mackie K. An Evaluation of Understudied Phytocannabinoids and Their Effects in Two Neuronal Models. Molecules. 2021. 26(17).
  • Scheyer AF, Borsoi M, Wager-Miller J, Pelissier-Alicot AL, Murphy MN, Mackie K*, Manzoni OJJ*. Cannabinoid Exposure via Lactation in Rats Disrupts Perinatal Programming of the Gamma-Aminobutyric Acid Trajectory and Select Early-Life Behaviors. Biol Psychiatry. 2020. 87(7): p.666-77. *Equal contribution
  • Chen HT, Mackie K. Adolescent Delta(9)-Tetrahydrocannabinol Exposure Selectively Impairs Working Memory but Not Several Other mPFC-Mediated Behaviors. Front Psychiatry. 2020. 11: p.576214.

View additional publications